Abstract

Quality of life in patients with liver metastases from colorectal cancer treated with first-line selective internal radiotherapy (SIRT): EQ-5D, EORTC QLQ-C30 and LMC21 results from the FOXFIRE study

Type: Abstract

Category: Gastrointestinal tumours, colorectal

Authors: J. Wolstenholme¹, F. Fusco¹, A.M. Gray¹, I. Chau², L. Dunham³, A. Roberts⁴, S. Love⁵, J. Moschandreas⁵, P. S. Virdee⁵, G. Van Hazel⁶, P. Gibbs⁷, Val Gebski⁸, V. Lewington⁹, G. Wilson¹⁰, P. Tait¹¹, N. Khan¹², D. Berry¹³, A. Wotherspoon¹⁴, B. Morgan¹⁵, S. Pearson¹⁶, A. Francis¹⁶, A. Al-Nahhas¹⁷, H. Wasan¹⁷, R. A. Sharma¹⁸;

¹Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, GB, ²Oncology, Royal Marsden Hospital, London, GB, ³Clinical Research, Oncology Clinical Trials Office, University of Oxford, Oxford, GB, ⁴Addenbrooke's Hospital, Cambridge Cancer Trials Centre, Cambridge, GB ⁵Centre for Statistics in Medicine, University of Oxford, Oxford, GB, ⁶University of Western Australia, Perth, WA, AU, ⁷Western Hospital, Footscray, VIC, AU, ⁸NHMRC Clinical Trials Centre, University of Sydney, AU, ⁹Nuclear Medicine Department, Guy's Hospital, King's College London, London, GB, ¹⁰Oncology, The Christie NHS Foundation Trust, Manchester, GB, ¹¹Radiology, Imperial College Healthcare NHS Trust & Imperial College, London, GB, ¹²Radiology, Royal Marsden and Chelsea & Westminster Hospital, London, GB, ¹³Department of Surgery, University Hospital Southampton, Southampton, GB, ¹⁴Pathology, The Royal Marsden NHS Foundation Trust, London, GB, ¹⁵Radiology, University of Leicester, Leicester, GB, ¹⁶Oncology Clinical Trials Office, Department of Oncology, University of Oxford, GB, ¹⁷Oncology, Imperial College Healthcare NHS Trust & Imperial College, London, GB, ¹⁸UCL Cancer Institute, NIHR University College London Hospitals Biomedical Research Centre, London, GB

Background

Little is known about quality of life (QoL) in colorectal cancer patients with liver metastases treated with selective internal radiotherapy (SIRT) using Yttrium-90 resin microspheres combined with FOLFOX (standard chemotherapy) compared to FOLFOX alone. We report QoL results from a multicentre randomized trial: FOXFIRE.

Methods

Patients were randomized to FOLFOX or FOLFOX+SIRT. All patients received EORTC QLQ-C30, LMC21 and EQ-5D (3 level) questionnaires at baseline, cycle-4, and yearly. We

compared mean QoL scores between arms at each timepoint, adjusting for baseline scores, using a 5% significance level. No missing data was imputed.

Results

364 patients were randomised overall. Questionnaire response rates ranged from 88% (321/364) at baseline to 58% (157/273) at 12 months.

Patients randomised to SIRT showed significantly ($p<0.05$) worse scores at cycle 4 on 2 of 9 QLQ-C30 symptom scales (dyspnea, appetite loss), with significantly better scores for constipation and diarrhea. SIRT patients had significantly worse functioning scores on 3 of 6 scales at 12 months follow up (physical, social and global health), and significantly more pain. No other QLQ-C30 scales showed significant differences.

On the LMC21 SIRT patients exhibited significantly worse nutrition and fatigue scores ($p<0.05$) and significantly better sore mouth and peripheral neuropathy scores at cycle 4. At 12 months follow up SIRT patients had significantly worse scores on 2 of the 13 symptoms (fatigue and dry mouth).

SIRT patients showed an EQ-5D decrement of 0.07 ($p=0.06$) at 12 months, but no differences at other timepoints.

Conclusions

SIRT patients did not have consistently worse QoL during treatment, but had lower functioning scores at 12 months compared with FOLFOX alone. QLQ-C30 and LMC21 differences were consistent with the EQ-5D decrement for SIRT patients at 12 months. Significant clinical important differences were detected only for pain at 12 months on the QLQ-C30 and peripheral neuropathy at cycle 4 on the LMC21.

Clinical trial identification

FOXFIRE ISRCTN83867919;